David Dai
Stock Analyst at Bernstein
(2.05)
# 3,039
Out of 5,140 analysts
31
Total ratings
46.43%
Success rate
-5.2%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SONY Sony Group | Maintains: Outperform | $33 → $30 | $23.68 | +26.69% | 1 | Jan 14, 2026 | |
| ASML ASML Holding | Upgrades: Outperform | $935 → $1,528 | $1,360.09 | +12.35% | 1 | Jan 5, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $18 → $7 | $2.55 | +174.51% | 2 | Nov 21, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $8.72 | +83.49% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $118.00 | -0.85% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $20.52 | +85.19% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $109.04 | +21.06% | 3 | Oct 31, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $7.31 | +173.60% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $19.02 | +36.70% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $16.85 | +78.04% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $2 | $2.51 | -20.32% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $11.60 | +106.90% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $35.25 | -31.91% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $13.27 | +419.97% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $36.01 | +38.85% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $57.13 | +5.02% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $8.07 | +5,451.43% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $75.10 | -46.74% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.75 | +2,192.26% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.20 | +2,172.73% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $29.07 | +78.88% | 1 | Mar 17, 2020 |
Sony Group
Jan 14, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $23.68
Upside: +26.69%
ASML Holding
Jan 5, 2026
Upgrades: Outperform
Price Target: $935 → $1,528
Current: $1,360.09
Upside: +12.35%
Perspective Therapeutics
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $7
Current: $2.55
Upside: +174.51%
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $8.72
Upside: +83.49%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $118.00
Upside: -0.85%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $20.52
Upside: +85.19%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $109.04
Upside: +21.06%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $7.31
Upside: +173.60%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $19.02
Upside: +36.70%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $16.85
Upside: +78.04%
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.51
Upside: -20.32%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $11.60
Upside: +106.90%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $35.25
Upside: -31.91%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $13.27
Upside: +419.97%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $36.01
Upside: +38.85%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $57.13
Upside: +5.02%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $8.07
Upside: +5,451.43%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $75.10
Upside: -46.74%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.75
Upside: +2,192.26%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.20
Upside: +2,172.73%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $29.07
Upside: +78.88%